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Abstract
Background: The prevalence of coronary artery diseases is low among Down Syndrome (DS) patients and they
rarely die of atherosclerotic complications. Histopathological investigations showed no increase in atherosclerosis,
or even a total lack of atherosclerotic changes, in DS
Aim: The aim of our study is to investigate the relationship between age and brain-derived neurotrophic factor
(BDNF) levels in Down Syndrome (DS).
Subjects and methods: Three groups of DS patients were studied: the first consisted of 23 children (age 2-14
years); the second of 14 adults (age 20-50 years), the third group of 13 elderly persons (>60 years) and a controls
group of 20 healthy patients (age 15-60 years).
The analytes of interest were quantified using a biochip array analyzer (Evidence®, Randox Ltd., Crumlin, UK).
Results: Plasma BDNF was higher in DS patients than in controls and there was a significant age-related increase.
Serum levels of IL-6 and MCP-1 were also higher in DS children and adults, but not in older patients, than in
healthy control. High levels of circulating BDNF may protect DS patients from the clinical complications of
atherosclerosis. However, the striking drop in peripheral BDNF levels with age might predispose these patients to
clinical manifestations of dementia in later life.
Introduction
The prevalence of coronary artery diseases is low among
Down Syndrome (DS) patients and they rarely die of
atherosclerotic complications [1]. Histopathological
investigations showed no increase in atherosclerosis, or
even a total lack of atherosclerotic changes, in DS [2].
Therefore, in spite of some classical biochemical risk
factors for atherosclerosis, its clinical manifestation is
low in DS. The reasons remain unclear, but recent stu-
dies have reported the potential importance of neurotro-
phins, such as nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF), in atherosclerosis
and related disorders [3]. In particular, in DS patients
interplay between NGF and inflammatory molecules IL-
6 and MCP-1, have been described [4]. Brain-derived
neurotrophic factor (BDNF) belongs to the neurotro-
phins family of proteins which, besides their neuro-
trophic functions, enhance survival and activity of a
large number of non-neuronal cells [5,6]. BDNF is
involved in mental retardation phenotype of DS. The
phenotype of Down syndrome, trisomy of chromosome
21, is hypothesized to be produced by the increased
expression due to gene dosage of normal chromosome
21 genes, which affects the regulation and function of
several proteins (ELK, CREB, ER, GR) and BDNF, which
are involved in certain facets of learning, memory and
behavior that are abnormal in DS or mouse models [7].
This loss of regulation may be particularly significant in
the etiology of neurodegenerative diseases that have a
significant impact on the aging brain such as AD, Par-
kinson’s disease, and autoimmune diseases [8,9]. It is of
interest that DS patients have a high risk of developing
Alzheimer’s disease (AD) [4]. Although the neuropatho-
logical characteristics appear similar, it is not known
whether the early-onset dementia seen in individuals
with DS originates from the same biological mechanisms
as in AD. Aging is a relevant factor affecting BDNF’s
ability to protect neuronal activity, but age related
effects on BDNF function in non neuronal cells, in par-
ticular in atherosclerosis, still remain unclear. * Correspondence: mmcorsi@unimi.it
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of circulating BDNF in DS and its relationship with IL-6
and MCP-1 in DS patients of different ages. BDNF
might be a protective biomarker for the clinical manifes-
tation of atherosclerosis in DS.
Subjects and methods
Subjects
Three groups of DS patients were studied: the first con-
sisted of 23 children (age 2-14 years); the second of 14
adults (age 20-50 years), the third group of 13 elderly
persons (>60 years) and a control group of 30 healthy
patients (age 2-65 years). All DS patients were assessed
by clinical examination and karyotype analysis; they had
mild and variable degrees of mental retardation, no
other pathological conditions at the time of the study,
and were in good health. The project was approved by
the University of Milan Ethics Committee and by the
Fondazione Antoniana of Bologna, Italy.
Methods
Blood samples were collected from DS patients. Plasma
was obtained by centrifugation, transferred into coded
plastic tubes, rapidly frozen and stored at -20°C until
analysis. The analytes of interest were quantified using a
biochip array analyzer (Evidence®, Randox Ltd., Crumlin,
UK). A biochip is a solid substrate where each specific
ligand (antibodies) is spotted on discrete test regions.
After an immuno-enzymatic reaction, each spot gener-
ates a chemiluminescent signal on the array which is
captured by a charge-coupled camera (CCD-camera)
and converted by image processing software to provide
results comparable with calibration curves.
Results
Our data show a statistically increase of serum BDNF
levels (fig. 1A) in Down’ss y n d r o m ep a t i e n t s( 4 8 . 2 8±
24.14 SD pg/mL), with an age range between 6 and 50
years, compared to healthy controls (8.96 ± 2.13 SD pg/
mL, p = 0.0003) with similar age range. On the same
patients two molecules involved in inflammatory pro-
cesses, IL-6 and MCP-1, were studied. Fig. 1B shows a
significant increase of IL-6 levels in Down’ss y n d r o m e
patients (77.75 ± 65.07 SD pg/mL) compared to controls
(7.94 ± 3.38 SD pg/mL with a p = 0.0140). Similarly
serum level of MCP-1, shown in fig 1C, increases statis-
tically in Down’s syndrome patients (198.44 ± 94.20 SD
pg/mL) compared to healthy controls (108.55 ± 25.25
SD pg/mL with a p = 0.0067).
Fig 2A shows that BDNF level is statistically significa-
tively higher than control subjects of the same age range
(children Down’s syndrome patients 36.94 ± 22.15 SD
pg/mL, children control 7.178 ± 0.468, p < 0.05; adult
Down’s syndrome patients 44.98 ± 21.34 SD pg/mL,
adult control 8.14 ± 1.274 SD pg/mL, p < 0.001; old
Down’s syndrome patients 69.83 ± 22.15 SD pg/mL, old
control 11.245 ± 1.035 SD pg/mL, p < 0.001). Among
Down’s syndrome patients, BDNF level increases in old
(>60 years old) patients (69.83 ± 22.15 SD pg/mL) com-
pared to both children (2-14 years old, 36.94 ± 22.15 SD
pg/mL with p < 0.01) and adults (20-50 years old)
Down’s syndrome patients (44.98 ± 21.34 SD pg/mL
with p < 0.01). Opposite trend is observed for IL-6
serum levels. Data shown in fig 2B indicate a statistically
decrease in old Down’s syndrome patients (33.17 ±
31.77 SD pg/mL) compared to children Down’ss y n -
drome patients (111.28 ± 76.02 SD pg/mL with p <
0.05) and a not statistically decrease compared to adults
Down’ss y n d r o m ep a t i e n t s( 6 6 . 0 5±5 0 . 3 8S Dp g / m L ) .
Also in this case DS patients levels differ form control
subject of the same age (children Down’ss y n d r o m e
patients 111.28 ± 76.02 SD pg/mL, children control
10.259 ± 1.403 SD pg/mL, p < 0.01; adult Down’ss y n -
drome patients 66.05 ± 50.38 SD pg/mL, adult control
6.57 ± 2.148 SD pg/mL, p > 0.05; old Down’ss y n d r o m e
patients 33.17 ± 31.77 SD pg/mL, old control 4.686 ±
1.756 SD pg/mL, p > 0.05)
Also MCP-1 serum level (fig 2C), displayed a statisti-
cally significative decrease in old Down’ss y n d r o m e
patients (103.78 ± 42.11 SD pg/mL) compared to chil-
dren Down’s syndrome patients (252.09 ± 91.06 SD pg/
mL, p < 0.001) while it showed a not statistically signifi-
cative decrease compared to adults Down’ss y n d r o m e
patients (174.99 ± 62.29 SD pg/mL, p > 0.05). DS
patients levels differ form control subject of the same
age (children Down’s syndrome patients 252.09 ± 91.06
SD pg/mL, children control 125.20 ± 18.682 SD pg/mL,
p < 0.001; adult Down’s syndrome patients 174.99 ±
62.29 Sd pg/mL, adult control 89.167 ± 8.91 SD pg/mL,
p > 0.05; old Down’s syndrome patients 103.78 ± 42.11
SD pg/mL, old control 78.8 ± 9.911 SD pg/mL, p >
0.05)
Down’s Syndrome patients maintain the same age
related trend observed for the three molecules in old
controls compared to adult and children ones. Further-
more, these ages related differences in serum levels of
BDNF, IL-6 and MCP-1 are not statistically significative
in control subjects, while in Down’ss y n d r o m ep a t i e n t s
are much more evident and statistically significative.
In particular, Fig 2A shows that level of BDNF dis-
plays a not statistically increase in old controls (11.245
± 1.035 SD pg/mL) compared to adult controls (8.140
± 1.274 SD pg/mL, (p > 0.05) and children controls
(7.177 ± 0.469 SD pg/mL p > 0.05). Opposite trend is
observed for IL-6 serum levels. Data shown in fig 2B
indicate a not statistically decrease in old controls
(4.686 ± 1.756 SD pg/mL) compared to adult controls
( 6 . 5 7±2 . 1 4 8S Dp g / m Lp>0 . 0 5 )a n dc h i l d r e n
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Figure 1 A Graphical representation of BDNF levels in DS patients compared healthy subject. B Graphical representation of IL-6 levels in
DS patients compared healthy subject. C Graphical representation of MCP-1/CCL-2 levels in DS patients compared healthy subject.
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Page 3 of 6Figure 2 A Graphical representation of BDNF levels in controls and DS patients subdivided in different age-range.BG r a p h i c a l
representation of IL-6 levels in controls and DS patients subdivided in different age-range C Graphical representation of MCP-1/CCL-2 levels in
controls and DS patients subdivided in different age-range.
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Page 4 of 6controls (10.259 ± 1.403 SD pg/mL p > 0.05). Fig 2C
displayed a not statistically decrease of MCP-1 levels
in old controls (78.8 ± 9.311 SD pg/mL) compared to
adult controls (89.167 ± 8.909 SD pg/mL p > 0.05)
and children controls (125, 2 ± 18.682 SD pg/mL e
p > 0.05).
The results are given as mean ± standard deviation
(SD). Groups were compared by one-way analysis of
variance. Linear regression analysis between experimen-
tal variables was also performed. Significance was taken
as p < 0.05. Post-hoc comparisons within logical sets of
means were performed using the Tukey-Kramer multi-
ple comparison test (GraphPad Software Inc., San Diego
CA).
Discussion
DS is considered a condition with a low risk of clinical
atherosclerosis and cardiovascular disease during adult
and later life. An increment of molecules with functional
roles in endothelial cell activation should raise the risk
of atherosclerosis in DS. However, since DS is consid-
ered an atheroma-free model [2] and clinical investiga-
tions do not report any rise in the risk of cardiovascular
disease in adult and elderly patients, DS patients consti-
tute a still unsolved biological/clinical paradox [4].
Questions remain about the role of BDNF in athero-
sclerosis. We do not know why the level BDNF appears
to be significantly depleted in humans with coronary
atherosclerosis [10,11]. The fact that plasma BDNF
levels are significantly reduced in the chronic, advanced
[3] and acute stages [10] of coronary atherosclerosis
points to a potential role of a deficit of this neurotro-
phin in atherosclerosis pathogenesis [12]. Neurotrophins
are potentially important in atherosclerosis and related
disorders [3,5]. A significant decrease in plasma NGF
and BDNF was associated with the metabolic syndrome
and atherosclerosis [13]. Age-related neurodegeneration
associated with AD correlates with changes in BDNF
expression too [8]. Recent investigations have looked
into the hypothesis of a possible diurnal variation of
BDNF circulating levels in human males. A correlation
with cortisol circadian rhythm has also been sought,
since both BDNF and cortisol are implicated in the
maintenance of cerebral functions [14]. It has been sug-
gested that BDNF might stimulate the production of
proteins involved in cellular stress adaptation, growth
and repair, neurogenesis, learning and memory and cell
survival. There is also evidence that an increase of
BDNF in either plasma or tissue has therapeutic poten-
tial [13]. Taking into account that BDNF is required for
survival and function of hippocampal, cortical, basal
forebrain, and entorhinal cortex neurons, and that in DS
the neuropathological aspects are complex and include
development of Alzheimer’s disease (AD) in older age,
we wanted to evaluate the change in BDNF levels in dif-
ferent age groups of Down’s Syndrome patients, com-
pared to the same age range healthy controls. Here we
show an age-related increase of BDNF level DS patients
serum, thus indicating a protective role of this molecule
against atherosclerosis risk as observed by Nelson at al
[15], showing that BDNF increase with age in healthy
subject. Our data confirmed this age related increase in
healthy control subjects, even if not statistically signifi-
cative, and moreover it pointed out that this BDNF level
increase is significatively higher in DS patients, in parti-
cular in old ones. In addition, among DS patients, this
increase fits with an age related and progressive
decrease of the proinflammatory and atherogenic cyto-
kines IL-6 and MCP-1. Here we showed that plasma IL-
6 and MCP-1 levels were elevated in DS compared to
control subject, further supporting the notion of vessel
dysfunction. This elevated level could not be ascribed to
clinical inflammation, since DS patients had no clinically
detectable pathological conditions. Therefore, it is likely
that the plasma high level of pro-inflammatory cytokines
in DS patients is due to endothelial activation without
activation of immune responses. Elevated levels of IL-6
and intercellular adhesion molecules have been asso-
ciated with endothelial dysfunction in various pathologi-
cal conditions, such as atherosclerosis and its
complications [9]. However, our results indicate that
these elevated serum levels of the pro-inflammatory and
atherogenic cytokines IL-6 and MCP-1 in DS patients,
progressively decrease with age, in parallel with an age
related increase of BDNF level.
Conclusion
we suggest that in DS patients, elevated peripheral
BDNF may protect against atherosclerosis, in particular
in old DS people. In these patients, the higher incidence
of dementia typically observed Down’ss y n d r o m eo l d
s u b j e c t s ,m a yi n d u c eas i g n i f i c a n ti n c r e a s eo fp l a s m a
BDNF, as a protective response to prevent learning,
memory functions and behavior degeneration.
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